# Modeyso (dordaviprone) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/dordaviprone

> The FDA approved Modeyso (dordaviprone), sponsored by Jazz Pharmaceuticals plc (JAZZ), on Aug 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Modeyso (dordaviprone) |
| Codes | ONC201 |
| Sponsor | Jazz Pharmaceuticals plc (JAZZ) https://sec-api.dev/companies/jazz/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | accelerated, fast track, orphan, priority review |

## Timeline

### Aug 2025: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-11-05, last confirmed 2025-11-05.
- Press release filed with the SEC (EX-99) (accession 0001232524-25-000073): "•Modeyso received accelerated approval from the FDA ahead of its PDUFA date; initiated commercial launch in August 2025 with strong initial uptake and sales of $11.0 million in 3Q25." https://www.sec.gov/Archives/edgar/data/1232524/000123252425000073/a3q25financialpr.htm

### August 18, 2025: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2025-03-05, last confirmed 2025-11-05.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-087233): "Dordaviprone is currently under Priority Review by the U.S. Food and Drug Administration (FDA), with a Prescription Drug User Fee Act (PDUFA) action date set for August 18, 2025." https://www.sec.gov/Archives/edgar/data/1232524/000119312525087233/d887871dex991.htm
- SEC Form 10-Q (accession 0001232524-25-000063): "For example, our recently acquired product candidate dordaviprone has a target PDUFA action date of August 18, 2025." https://www.sec.gov/Archives/edgar/data/1232524/000123252425000063/jazz-20250630.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-046226): "FDA has set a target Prescription Drug User Fee Act (PDUFA) action date of August 18, 2025." https://www.sec.gov/Archives/edgar/data/1232524/000119312525046226/d927269dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-046226): "NDA has been granted Priority Review and assigned a PDUFA target action date of August 18, 2025" https://www.sec.gov/Archives/edgar/data/1232524/000119312525046226/d927269dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001232524-25-000025): "•Acquisition of Chimerix added dordaviprone to late-stage pipeline, representing near-term commercial opportunity; PDUFA target data of August 18, 2025." https://www.sec.gov/Archives/edgar/data/1232524/000123252425000025/a1q25financialpr.htm
- SEC Form 10-Q (accession 0001232524-25-000063): "FDA has set a target PDUFA action date of August 18, 2025." https://www.sec.gov/Archives/edgar/data/1232524/000123252425000063/jazz-20250630.htm
- SEC Form 10-Q (accession 0001232524-25-000027): "FDA has set a target PDUFA action date of August 18, 2025." https://www.sec.gov/Archives/edgar/data/1232524/000123252425000027/jazz-20250331.htm
- Press release filed with the SEC (EX-99) (accession 0001232524-25-000073): "•Modeyso received accelerated approval from the FDA ahead of its PDUFA date; initiated commercial launch in August 2025 with strong initial uptake and sales of $11.0 million in 3Q25." https://www.sec.gov/Archives/edgar/data/1232524/000123252425000073/a3q25financialpr.htm
- Press release filed with the SEC (EX-99) (accession 0001232524-25-000061): "FDA has set a target PDUFA action date of August 18, 2025." https://www.sec.gov/Archives/edgar/data/1232524/000123252425000061/a2q25financialpr.htm
- Press release filed with the SEC (EX-99) (accession 0001232524-25-000025): "FDA has set a target Prescription Drug User Fee Act (PDUFA) action date of August 18, 2025." https://www.sec.gov/Archives/edgar/data/1232524/000123252425000025/a1q25financialpr.htm

Calendar months: [August 2025](https://sec-api.dev/fda-calendar/2025-08)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/dordaviprone.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Modeyso (dordaviprone) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/dordaviprone

```bibtex
@misc{secapidev_pdufa_dordaviprone_20261116,
  title        = {Modeyso (dordaviprone) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/dordaviprone}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_dordaviprone_20261116","title":"Modeyso (dordaviprone) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/dordaviprone","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
